Cipla Limited – FDA 483, Apr 13, 2018

This FDA Form 483 document outlines observations made during an inspection, indicating deficiencies in the facility's operations related to drug product manufacturing and quality control.

The first observation notes that "Testing programs are not adequately designed to assess the stability characteristics of drug products." This suggests a failure in the facility's ability to ensure the long-term quality and safety of its drug products, potentially leading to products degrading or becoming ineffective over time.

Secondly, "Written procedures for production and process controls are not designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess." This indicates a fundamental flaw in the manufacturing process documentation and implementation, raising concerns about the consistency and reliability of the drug products produced. It implies that the established procedures are insufficient to guarantee that the final products meet their intended specifications.

Finally, "Scientifically sound and appropriate laboratory control mechanisms are not established to assure that in-process materials or drug products conform to appropriate standards of identity, strength, quality and purity." This observation points to a significant weakness in the laboratory's ability to monitor and control the quality of materials throughout the production cycle, from raw materials to finished products. Without robust laboratory controls, there is an increased risk of non-conforming materials being used or released, compromising the overall quality and safety of the drug products.

In summary, the Form 483 highlights critical deficiencies in stability testing, production and process control procedures, and laboratory